Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Cocrystal Pharma, Inc., formerly known as BioZone Pharmaceuticals, Inc.
OKLAHOMA CITY--(BUSINESS WIRE)--Sep 21, 2018--Federman & Sherwood announces that on September 20, 2018, a class action lawsuit was filed in the United States District Court for the District of New Jersey against Cocrystal Pharma, Inc., f/k/a BioZone Pharmaceuticals, Inc. (NASDAQ: COCP). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is September 23, 2013 through September 7, 2018.
Plaintiff seeks to recover damages on behalf of all Cocrystal Pharma, Inc., f/k/a BioZone Pharmaceuticals, Inc. shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above. You may move the Court no later than Monday, November 19, 2018 to serve as a lead plaintiff for the entire Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.
If you wish to discuss this action, obtain further information and participate in this or any other securities litigation, or should you have any questions or concerns regarding this notice or preservation of your rights, please contact:
View source version on businesswire.com:https://www.businesswire.com/news/home/20180921005413/en/
CONTACT: Federman & Sherwood
KEYWORD: UNITED STATES NORTH AMERICA OKLAHOMA
INDUSTRY KEYWORD: PROFESSIONAL SERVICES LEGAL
SOURCE: Federman & Sherwood
Copyright Business Wire 2018.
PUB: 09/21/2018 11:41 AM/DISC: 09/21/2018 11:41 AM